Pulse intravenous cyclophosphamide for treatment of autoimmune blistering disease. Is there an advantage over oral routes?
Werth
V P
VP
D000284:Administration, Oral; D000477:Alkylating Agents / Q000008:administration & dosage*; D001327:Autoimmune Diseases / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000008:administration & dosage*; D006801:Humans; D007275:Injections, Intravenous; D012871:Skin Diseases / Q000188:drug therapy* / Q000276:immunology
D000477:Alkylating Agents; D003520:Cyclophosphamide